1 ls that we termed "hyper-immune CD20Hi" and "pauci-immune CD20Lo." Of note, subjects had only one inf

2  found that a dose of 1600 microg/kg induced pauci-immune crescentic glomerulonephritis and lung hemo

3 sis (not collapsing glomerulopathy variant), pauci-immune crescentic glomerulonephritis, acute inters

4                                              Pauci-immune focal necrotizing GN (piFNGN) is usually as

5   Thus, anti-MPO IgG alone was able to cause pauci-immune glomerular necrosis and crescent formation

6 ti-neutrophil cytoplasmic antibodies-related pauci-immune glomerulonephritis.

7 pecific disease entities: immune-complex GN, pauci-immune GN, antiglomerular basement membrane GN, mo

8 ial who had renal involvement (biopsy proven pauci-immune GN, red blood cell casts in the urine, and/

9 antineutrophil cytoplasmic antibody-positive pauci-immune GN.

10 culating anti-MPO resulted in development of pauci-immune NCGN in all mice and pulmonary capillaritis

11 perimental evidence indicate that ANCA cause pauci-immune necrotizing and crescentic glomerulonephrit

12  strongly associated with the development of pauci-immune necrotizing and crescentic glomerulonephrit

13 lation of approximately 80% of patients with pauci-immune necrotizing and crescentic glomerulonephrit

14 tis), the Churg-Strauss syndrome, idiopathic pauci-immune necrotizing and crescentic glomerulonephrit

15                                    Excluding pauci-immune necrotizing and crescentic glomerulonephrit

16 tinct forms of small vessel vasculitides and pauci-immune necrotizing glomerulonephritis.

17               Anti-PR3 treated mice had mild pauci-immune proliferative glomerulonephritis, with infi

18                               In populations pauci-immune to malaria, risk of severe malaria increase